Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Liquidia Technologies ( (LQDA) ) has shared an announcement.
On May 12, 2025, Liquidia Corporation announced that United Therapeutics Corporation filed a complaint against them on May 9, 2025, in the U.S. District Court for the Middle District of North Carolina. The complaint alleges infringement of U.S. Patent No. 11,357,782 and seeks to prevent Liquidia from commercializing YUTREPIA™ if it receives FDA approval. Despite the litigation, the FDA’s ability to take final action on the New Drug Application for YUTREPIA by the PDUFA goal date of May 24, 2025, remains unaffected. Liquidia’s CEO, Dr. Roger Jeffs, expressed determination to defend patient access to alternative therapies, highlighting past successes in invalidating similar patent claims.
Spark’s Take on LQDA Stock
According to Spark, TipRanks’ AI Analyst, LQDA is a Neutral.
Liquidia Technologies is currently facing significant financial challenges, with declining revenues and high leverage posing risks. However, the company’s strong liquidity position and strategic initiatives, including the potential launch of YUTREPIA, offer some positive outlook. Technical analysis indicates upward stock momentum, but unprofitability and lack of dividend yield affect its valuation negatively. Mixed earnings call sentiment reflects both strategic advancements and financial difficulties.
To see Spark’s full report on LQDA stock, click here.
More about Liquidia Technologies
Liquidia Corporation is a biopharmaceutical company focused on developing innovative therapies for patients with rare cardiopulmonary diseases. The company is known for its proprietary PRINT® Technology, which has led to the creation of YUTREPIA™ (treprostinil) inhalation powder, an investigational drug for treating pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). Liquidia also markets a generic Treprostinil Injection for PAH and is developing L606, a sustained-release formulation of treprostinil.
Average Trading Volume: 1,099,731
Technical Sentiment Signal: Buy
Current Market Cap: $1.3B
See more insights into LQDA stock on TipRanks’ Stock Analysis page.